Related Experiment Video
Updated: Dec 2, 2025

Preclinical Model of Prenatal Delta-9-Tetrahydrocannabinol Exposure to Assess Its Impact on Neurodevelopmental Outcomes
Published on: February 28, 2025
Preterm Birth and 17OHP - Why the FDA Should Not Withdraw Approval
Michael F Greene1, Mark A Klebanoff1, David Harrington1
1From the Department of Obstetrics and Gynecology, Massachusetts General Hospital (M.F.G.), the Harvard T.H. Chan School of Public Health (D.H.), and the Dana-Farber Cancer Institute (D.H.) - all in Boston; and Nationwide Children's Hospital, Ohio State University College of Medicine, and Ohio State University College of Public Health - all in Columbus (M.A.K.).
No abstract available in PubMed .
More Related Videos
09:04Comprehensive Evaluation of the Effectiveness and Safety of Placenta-Targeted Drug Delivery Using Three Complementary Methods
Published on: September 10, 2018
04:53A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
Related Concept Videos
Drug Regulation
Teratogenicity
FDA Approved Drugs: Changes to Approved Drugs
Factors Affecting Drug Response: Overview
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...